Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan

Substance Abuse: Treatment, Prevention, and Policy

Volumn 7, Issue , 2012, Pages

  Lee, Hsin Ya ^a   Li, Jih Heng ^a   Wu, Li Tzy ^b   Wu, Jin Song ^c   Yen, Cheng Fang ^d,e   Tang, Hsin Pei ^f  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Bureau of National Health Insurance Taiwan   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f Jianan Mental Hospital   (Taiwan)

Author keywords

Adverse drug reactions or ADR; Benzodiazepines; Methadone maintenance program; Methadone drug interactions; QTc prolongation effect

Indexed keywords

ANTIDEPRESSANT AGENT; HYPNOTIC SEDATIVE AGENT; METHADONE; NARCOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; DRUG INTERACTION; FEMALE; HEART ARRHYTHMIA; HEPATITIS B; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PROSPECTIVE STUDY; RESPIRATORY FAILURE; RISK FACTOR; TAIWAN; WITHDRAWAL SYNDROME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ARRHYTHMIAS, CARDIAC; DRUG INTERACTIONS; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; HYPNOTICS AND SEDATIVES; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROSPECTIVE STUDIES; RESPIRATORY INSUFFICIENCY; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; TAIWAN;

EID: 84862778232     PISSN: None     EISSN: 1747597X     Source Type: Journal    
DOI: 10.1186/1747-597X-7-11     Document Type: Article

References (68)

1. Corkery JM, Schifano F, Ghodse AH, Oyefeso A. The effects of methadone and its role in fatalities. Hum Psychopharmacol 2004, 19:565-576. 10.1002/hup.630, 15378662.
2. Bilban M, Bilban Jakopin C. Methadone maintenance treatment and drugs. Coll Antropol 2002, 26:107-117.
3. Trussell RE, Gollance H. Methadone maintenance treatment is successful for heroin addicts. Hosp Manage 1970, 110:56-62.
4. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (Heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 1965, 193:646-650. 10.1001/jama.1965.03090080008002, 14321530.
5. Burt RD, Hagan H, Garfein RS, Sabin K, Weinbaum C, Thiede H. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004. J Urban Health 2007, 84:436-454. 10.1007/s11524-007-9178-2, 2231834, 17356901.
6. Willner-Reid J, Belendiuk KA, Epstein DH, Schmittner J, Preston KL. Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat 2008, 35:78-86. 10.1016/j.jsat.2007.08.011, 2600879, 17931826.
7. Dinnen AH. Methadone dosage and retention of patients in maintenance treatment. Med J Aust 1991, 155:278.
8. de Perez Los Cobos J, Trujols J, Valderrama JC, Valero S, Puig T. Patient perspectives on methadone maintenance treatment in the Valencia Region: dose adjustment, participation in dosage regulation, and satisfaction with treatment. Drug Alcohol Depend 2005, 79:405-412. 10.1016/j.drugalcdep.2005.03.021, 15869846.
9. Siassi I, Angle BP, Alston DC. Maintenance dosage as a critical factor in methadone maintenance treatment. Br J Addict Alcohol Other Drugs 1977, 72:261-268.
10. Maremmani I, Nardini R, Zolesi O, Castrogiovanni P. Methadone dosages and therapeutic compliance during a methadone maintenance program. Drug Alcohol Depend 1994, 34:163-166. 10.1016/0376-8716(94)90138-4, 8026304.
11. Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000, 356:2069-2070. 10.1016/S0140-6736(00)03409-7, 11145498.
12. Nielsen S, Dietze P, Cantwell K, Lee N, Taylor D. Methadone- and buprenorphine-related ambulance attendances: a population-based indicator of adverse events. J Subst Abuse Treat 2008, 35:457-461. 10.1016/j.jsat.2007.12.007, 18295435.
13. Bao YP, Liu ZM, Epstein DH, Du C, Shi J, Lu L. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse 2009, 35:28-33. 10.1080/00952990802342899, 19152203.
14. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003, CD002208.
15. Leavitt SB, Shinderman M, Maxwell S, Eap CB, Paris P. When "enough" is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med 2000, 67:404-411.
16. Hallinan R, Byrne A, Agho K, McMahon C, Tynan P, Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med 2008, 5:684-692. 10.1111/j.1743-6109.2007.00702.x, 18093096.
17. Schmittner J, Schroeder JR, Epstein DH, Preston KL. Menstrual cycle length during methadone maintenance. Addiction 2005, 100:829-836. 10.1111/j.1360-0443.2005.01091.x, 15918813.
18. Fahey T, Law F, Cottee H, Astley P. Sudden death in an adult taking methadone: lessons for general practice. Br J Gen Pract 2003, 53:471-472. 1314622, 12939893.
19. Hendra TJ, Gerrish SP, Forrest AR. Fatal methadone overdose. BMJ 1996, 313:481-482. 10.1136/bmj.313.7055.481, 2351880, 8776322.
20. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003, 23:802-805. 10.1592/phco.23.6.802.32186, 12820821.
21. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002, 137:501-504.
22. Ridgway ZA, Pountney AJ. Acute respiratory distress syndrome induced by oral methadone managed with non-invasive ventilation. Emerg Med J 2007, 24:681. 10.1136/emj.2007.048991, 2464674, 17711964.
23. Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann P, Eap CB. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002, 22:211-215. 10.1097/00004714-200204000-00017, 11910269.
24. Moody DE, Fang WB, Lin SN, Weyant DM, Strom SC, Omiecinski CJ. Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes. Drug Metab Dispos 2009, 37:2323-2329. 10.1124/dmd.109.028605, 2784702, 19773542.
25. Lemesle F, Nicola W, Pierre Jonville-Bera A. First case of stress cardiomyopathy as a result of methadone withdrawal secondary to drug-drug interaction. Am J Emerg Med 2010, 28:387.e5-387.e6. e385-386, 10.1016/j.ajem.2009.07.007, 20223408.
26. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004, 76:250-269. 10.1016/j.clpt.2004.05.003, 15371986.
27. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004, 16:36-44. 10.1002/chir.10303, 14628297.
28. Eap CB, Broly F, Mino A, Hammig R, Deglon JJ, Uehlinger C, Meili D, Chevalley AF, Bertschy G, Zullino D, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001, 21:229-234. 10.1097/00004714-200104000-00016, 11270921.
29. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, De GarciaOlalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005, 100:981-989. 10.1111/j.1360-0443.2005.01089.x, 15955014.
30. Stocker H, Kruse G, Kreckel P, Herzmann C, Arasteh K, Claus J, Jessen H, Cordes C, Hintsche B, Schlote F, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004, 48:4148-4153. 10.1128/AAC.48.11.4148-4153.2004, 525438, 15504834.
31. Prosser JM, Mills A, Rhim ES, Perrone J. Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. Int J Emerg Med 2008, 1:217-220. 10.1007/s12245-008-0052-0, 2657284, 19384521.
32. Barry D, Weinstock J, Petry NM. Ethnic differences in HIV risk behaviors among methadone-maintained women receiving contingency management for cocaine use disorders. Drug Alcohol Depend 2008, 98:144-153. 10.1016/j.drugalcdep.2008.06.009, 2614896, 18684571.
33. Craig RJ, Olson RE. Predicting methadone maintenance treatment outcomes using the addiction severity index and the MMPI-2 content scales (Negative Treatment Indicators and Cynism scales). Am J Drug Alcohol Abuse 2004, 30:823-839. 10.1081/ADA-200037548, 15624551.
34. Jamois C, Smith P, Morrison R, Riek M, Patel A, Schmitt C, Morcos PN, Zhang X. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. Addict Biol 2009, 14:321-327. 10.1111/j.1369-1600.2009.00158.x, 19523046.
35. Taylor LE, Bowman SE, Chapman S, Zaller N, Stein MD, Cioe PA, Maynard MA, McGovern BH. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Drug Alcohol Depend 2011, 116:233-237. 10.1016/j.drugalcdep.2010.11.016, 21177046.
36. Batkis MF, Treisman GJ, Angelino AF. Integrated opioid use disorder and HIV treatment: rationale, clinical guidelines for addiction treatment, and review of interactions of antiretroviral agents and opioid agonist therapies. AIDS Patient Care STDS 2010, 24:15-22. 10.1089/apc.2009.0242, 20095910.
37. Li J, Liu S, Yu W. Patterns and Trends of Drug Abuse in Taiwan: A Brief History and Report from 2000 through 2004 in Epidemiologic trends in drug abuse Volume II. Proceedings of the Community Epidemiology Work Group June 2005 2006, National Institute on Drug Abuse, National Institutes of Health, U.S. Department of Health and Human Services.
38. Taiwan Centers for Disease Control (TCDC) Harm Reduction Programme. [Accessed 2010 Aug 31], from (In Mandarin), Taiwan Centers for Disease Control (TCDC)., http://www.cdc.gov.tw
39. Lee HY, Yang YH, Yu WJ, Su LW, Lin TY, Chiu HJ, Tang HP, Lin CY, Pan RN, Li JH. Essentiality of HIV testing and education for effective HIV control in the national pilot harm reduction program: the Taiwan experience. Kaohsiung J Med Sci 2012, 28:79-85. 10.1016/j.kjms.2011.10.006, 22313534.
40. Liu SF, Lee PC, Lu MI, Tsay WI, Li JH. A survey on substance abuse in the Greater Taipei area. Taiwan Journal of Public Health 2006, 25:274-282.
41. Thomson Micromedex Micromedex® Healthcare Series. Greenwood Village, Colorado Accessed 2010 Aug 31, Thomson Micromedex., http://newmdx.csis.com.tw/hcs/librarian
42. Lexi-Interact Online. Up-to-date. [Accessed 2010 Aug 31]., http://www.uptodate.com/index
43. Leavitt SB. Methadone-Drug Interactions (Medications, illicit drugs, & other substances). Pain Treatment Topics 2010, Glenview, IL: Mallinckrodt Pharmaceuticals., [Available as a PDF at http://pain-topics.org/pdf/Methadone-Drug_Intx_2006.pdf].
44. Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med 2008, 9:315-344. 10.1111/j.1526-4637.2006.00289.x, 18386306.
45. Meilera A, Minob A, Chattona A, Broersc B. Benzodiazepine use in a methadone maintenance programme: patient characteristics and the physician's dilemma. Schweiz Arch Neuorol Psychiatr 2005, 156:310-317.
46. Eiroa-Orosa FJ, Haasen C, Verthein U, Dilg C, Schafer I, Reimer J. Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance treatment: findings of the German randomized controlled trial. Drug Alcohol Depend 2010, 112:226-233. 10.1016/j.drugalcdep.2010.06.013, 20708349.
47. Cacciola JS, Alterman AI, Rutherford MJ, McKay JR, Mulvaney FD. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend 2001, 61:271-280. 10.1016/S0376-8716(00)00148-4, 11164691.
48. Carpentier PJ, Krabbe PF, van Gogh MT, Knapen LJ, Buitelaar JK, de Jong CA. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict 2009, 18:470-480. 10.3109/10550490903205652, 19874168.
49. Bramness JG, Kornor H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007, 90:203-209. 10.1016/j.drugalcdep.2007.03.008, 17478058.
50. Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis 2008, 27:37-48.
51. Chan GM, Stajic M, Marker EK, Hoffman RS, Nelson LS. Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: analysis of medical examiner data. Acad Emerg Med 2006, 13:543-547. 10.1111/j.1553-2712.2006.tb01006.x, 16641481.
52. Darke S, Duflou J, Torok M. The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend 2010, 106:1-6. 10.1016/j.drugalcdep.2009.07.014, 19720472.
53. Wolf BC, Lavezzi WA, Sullivan LM, Flannagan LM. Methadone-related deaths in Palm Beach County. J Forensic Sci 2004, 49:375-378.
54. Wolf BC, Lavezzi WA, Sullivan LM, Middleberg RA, Flannagan LM. Alprazolam-related deaths in Palm Beach County. Am J Forensic Med Pathol 2005, 26:24-27. 10.1097/01.paf.0000153994.95642.c1, 15725773.
55. Li L, Sangthong R, Chongsuvivatwong V, McNeil E, Li J. Lifetime multiple substance use pattern among heroin users before entering methadone maintenance treatment clinic in Yunnan, China. Drug Alcohol Rev 2010, 29:420-425. 10.1111/j.1465-3362.2009.00168.x, 20636659.
56. Manchikanti L, Damron KS, Pampati V, McManus CD. Prospective evaluation of patients with increasing opiate needs: prescription opiate abuse and illicit drug use. Pain Physician 2004, 7:339-344.
57. Man LH, Best D, Gossop M, Stillwell G, Strang J. Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment. Eur Addict Res 2004, 10:35-40. 10.1159/000073724, 14665804.
58. Kienbaum P, Scherbaum N, Thurauf N, Michel MC, Gastpar M, Peters J. Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns. Crit Care Med 2000, 28:969-976. 10.1097/00003246-200004000-00010, 10809268.
59. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Eap CB. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006, 80:668-681. 10.1016/j.clpt.2006.09.012, 17178267.
60. Bunten H, Liang WJ, Pounder D, Seneviratne C, Osselton MD. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 2011, 16:142-144. 10.1111/j.1369-1600.2010.00274.x, 21158011.
61. Raffa JD, Grebely J, Tossonian H, Wong T, Viljoen M, Khara M, Mead A, McLean M, Duncan F, Petkau AJ, et al. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. Drug Alcohol Depend 2007, 89:306-309. 10.1016/j.drugalcdep.2007.02.007, 17383117.
62. D'Souza R, Glynn MJ, Ushiro-Lumb I, Feakins R, Domizio P, Mears L, Alsced E, Kumar P, Sabin CA, Foster GR. Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol 2005, 3:910-917. 10.1016/S1542-3565(05)00527-6, 16234030.
63. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, Cheever LW, Cargill VA. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005, 40(Suppl 5):S276-S285. 1510897, 15768335.
64. Clemmey P, Brooner R, Chutuape MA, Kidorf M, Stitzer M. Smoking habits and attitudes in a methadone maintenance treatment population. Drug Alcohol Depend 1997, 44:123-132. 10.1016/S0376-8716(96)01331-2, 9088784.
65. Chisolm MS, Brigham EP, Tuten M, Strain EC, Jones HE. The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse. Am J Drug Alcohol Abuse 2010, 36:46-51. 10.3109/00952990903544844, 2925391, 20141396.
66. Bomsien S, Skopp G. An in vitro approach to potential methadone metabolic-inhibition interactions. Eur J Clin Pharmacol 2007, 63:821-827. 10.1007/s00228-007-0327-z, 17598095.
67. Elkader AK, Brands B, Selby P, Sproule BA. Methadone-nicotine interactions in methadone maintenance treatment patients. J Clin Psychopharmacol 2009, 29:231-238. 10.1097/JCP.0b013e3181a39113, 19440076.
68. Demarie D, Marletta G, Imazio M, Cappa C, Ferro S, Compostino R, De Vivo E, Trinchero R, Bignamini E. Cardiovascular-associated disease in an addicted population: an observation study. J Cardiovasc Med 2011, 12:51-54.